NCT05477576 2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
Clinical Trials
6 trialsNCT06943755 2026-03-24
STELLAR-311
Exelixis
Phase 2/3 Recruiting
NCT06472388 2024-06-25
EVENET
AC Camargo Cancer Center
Phase 2 Recruiting
NCT01374451 2016-12-20
COOPERATE-2
Novartis
Phase 2 Terminated
NCT00804336 2016-10-19
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00942682 2014-04-29
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 1 Completed